You are viewing the site in preview mode
Skip to main content
| | |
Cumulative Doxorubicin dose (mg m− 2)
| |
|---|
|
All patients
|
< 200
|
≥200
|
P-value
|
|---|
|
N (%)
|
35
|
14 (40%)
|
21 (60%)
| |
|
Age (year)
|
50.6 ± 13.2
|
50.3 ± 13.4
|
50.8 ± 13.4
|
NS
|
|
Female (%)
|
14 (40.0%)
|
5 (14.2%)
|
9 (25.8%)
|
NS
|
|
White (%)
|
21 (60.0%)
|
11 (31.4%)
|
10 (28.6%)
|
NS
|
|
Hyperlipidemia
|
18 (51.4%)
|
5 (14.3%)
|
13 (37%)
|
NS
|
|
Diabetes
|
19 (54.2%)
|
10 (28.6%)
|
9 (27.5%)
|
NS
|
|
Hypertension
|
27 (77.14%)
|
11 (31.4%)
|
16 (45.7%)
|
NS
|
|
Smoker (%)
|
13 (37.1%)
|
5 (14.3%)
|
8 (22.9%)
|
NS
|
|
COPD (%)
|
3 (0.9%)
|
2 (0.6%)
|
1 (0.3%)
|
NS
|
|
Heart rate (bpm)
|
89.1 ± 14.2
|
92.8 ± 17.2
|
86.6 ± 11.5
|
NS
|
|
BMI
|
27.9 ± 5.6
|
28.1 ± 5.7
|
27.8 ± 5.7
|
NS
|
- BMI Body Mass Index, bpm beats per minute, COPD chronic obstructive pulmonary disease
